Category: by institution

More on Anil Potti: Two other papers worth keeping an eye on

courtesy Duke

It’s fair to say that we haven’t heard the last of Anil Potti, the Duke cancer researcher who resigned last month following revelations that he had faked some of his results. Duke is still investigating the situation, and has also asked the Institute of Medicine to conduct its own study into the case and its ramifications.

This week, we may find out whether Nature Medicine will retract a paper that Joseph Nevins, one of Potti’s co-authors, asked the journal to withdraw last month. We’re also keeping an eye on two other papers that have already been the subject of increased scrutiny: Continue reading More on Anil Potti: Two other papers worth keeping an eye on

ORI comes down (hard) on Bengu Sezen, Columbia chemist accused of fraud

The Office of Research Integrity has thrown a heavy book at Bengu Sezen, a former chemist at Columbia University, alleging that school and agency investigators turned up 21 instances of research misconduct by the disgraced scientist.

According to the agency: Continue reading ORI comes down (hard) on Bengu Sezen, Columbia chemist accused of fraud

Another update on Anil Potti: Co-author asks Nature Medicine to retract paper

courtesy Nature

Anil Potti, who resigned from his post at Duke today during an investigation into faked results, will likely have another retraction to his credit shortly. According to a Duke statement:

Dr. Potti’s collaborator, Joseph Nevins, Ph.D., has initiated a process intended to lead to a retraction request regarding a paper previously published in Nature Medicine.  This process has been initiated due to concerns about the reproducibility of reported predictors, and their possible effect on the overall conclusions in this paper.  Other papers published based on this science are currently being reviewed for any concerns. Continue reading Another update on Anil Potti: Co-author asks Nature Medicine to retract paper

Duke’s Anil Potti resigns

Duke University photo

Duke’s Anil Potti, the Duke cancer researcher who falsely claimed to be a Rhodes Scholar and may have faked several analyses of chemotherapy and cancer, has resigned from the university.

The Duke Chronicle reports that Potti

…stepped down from his position at Duke’s Institute for Genome Sciences and Policy Friday and took responsibility for the problems in his research, IGSP Director Huntington Willard wrote in an e-mail to IGSP staff.

Willard wrote that Potti “accepted full responsibility for a series of anomalies in data handling, analysis and management that have come under scrutiny in the past months.”

He said that investigations into Potti’s research will continue, as will IGSP’s examinations of Potti’s science.

The resignation follows the retraction earlier this week of one paper Potti co-authored in the Journal of Clinical Oncology.

We’ll update as we learn more.

Please see an update about a second paper now being retracted by one of Potti’s co-authors.

JCO makes it official, retracting paper co-authored by Anil Potti

We have a follow-up to our post two weeks ago about a possible retraction in the case of Anil Potti, the Duke cancer researcher who falsely claimed to be a Rhodes Scholar and may have also faked an analysis of how breast cancer responds to chemotherapy.

In that post, we noted that the Raleigh News & Observer had reported that one of Potti’s collaborators, Duke’s Joseph Nevins, had requested that a 2007 paper they co-authored be retracted. The journal told us this morning that the retraction went live yesterday. In it, the authors write: Continue reading JCO makes it official, retracting paper co-authored by Anil Potti

A retraction in the Potti case?

In our very first post, we noted the case of Anil Potti,

a Duke researcher who posed as a Rhodes Scholar and appears to have invented key statistical analyses in a study of how breast cancer responds to chemotherapy[.The case] has sent ripples of angst through the cancer community. Potti’s antics prompted editors of The Lancet Oncology to issue an “expression of concern” — a Britishism that might be better expressed as “Holy Shit!” — about the validity of a 2007 paper in their journal by Potti and others.

There hasn’t been any further movement on The Lancet Oncology study, as far as we know, but on Friday the Raleigh News & Observer reported that one of Potti’s co-authors on a 2007 Journal of Clinical Oncology (JCO) paper had requested a retraction: Continue reading A retraction in the Potti case?

Scientist raised serious questions about 2008 Cell study by Amy Wagers

Amy Wagers, a Harvard stem cell researcher, retracted a Nature study last week and has another published paper under scrutiny at Blood. Retraction Watch has now learned that a 2008 Cell paper she co-authored drew significant criticism from a stem cell researcher at Children’s National Medical Center.

In the paper, Wagers and her team said they were able to prepare a set of muscle cells that reversed some of the effects of muscular dystrophy in a mouse model of the disease. In a 2008 letter to the editor of Cell, however, Terence Partridge wrote Continue reading Scientist raised serious questions about 2008 Cell study by Amy Wagers

Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Yesterday, we noted that Amy Wagers and Shane Mayack have published five papers together. One of those, published earlier this year in Nature, was retracted Wednesday, and another is now the subject of a “notice of concern” from Blood.

We wanted to find out about some of the other papers published by Wagers and Mayack, so we contacted the editor of Developmental Biology, which published one of them. They have not heard from Wagers or Harvard, but are monitoring developments, according to editor in chief Robb Krumlauf: Continue reading Editor of another journal where Wagers and Mayack published an abstract is monitoring the situation

Blood posts “notice of concern” over second Wagers-Mayack paper

A day after an up and coming Harvard stem cell scientist retracted a Nature paper, Blood has issued a notice of concern about another paper by the same group, published in August 2008, the Boston Globe reports. Such notices often, but not always, precede retractions.

According to the notice for “Osteolineage niche cells initiate hematopoietic stem cell mobilization”: Continue reading Blood posts “notice of concern” over second Wagers-Mayack paper

Highly cited Harvard stem cell scientist retracts Nature paper

courtesy Nature

Amy Wagers, an up and coming stem cell researcher at Harvard who made a name for herself as a postdoc early by questioning the work of others, has retracted a January 2010 paper she co-authored in Nature. According to the retraction:

Three of the authors (J.L.S., F.S.K. and A.J.W.) wish to retract this Article after a re-examination of the publication raised serious concerns with some of the reported data. These concerns have undermined the authors’ confidence in the support for the scientific conclusions reported, specifically the role of osteopontin-positive niche cells in the rejuvenation of haematopoietic stem cells in aged mice. Although this matter is under further review, these authors wish to retract the paper in its entirety, and regret any adverse consequences that may have resulted from the paper’s publication. The retraction has not been signed by Shane R. Mayack, who maintains that the results are still valid.